Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA

References

• Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012;148:349
   PubMed Web of Science ®Google Scholar
• Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008;3:157
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;15:1960
   Google Scholar
• Kulke MH, Blaszkowski LS, Ryan DP, et al. Capecitabine plus Erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007;25:4787
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46(Suppl 1):115S
   PubMedGoogle Scholar
• Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441
   PubMed Web of Science ®Google Scholar
• Yu L, Ju DW, Chen W, et al. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm 2006;21:5
   PubMedGoogle Scholar
• Chen S, Yu L, Jiang C, et al. Pivotal study of iodine-131-labeled chTNT radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 2005;23:1538
   PubMed Web of Science ®Google Scholar
• Khawli LA, Hu P, Epstein AL. Multiple uses of tumor necrosis therapy (TNT) for the treatment and imaging of solid tumors: preclinical considerations and progress. Update Cancer Ther 2006;1:33
   Google Scholar
• Gold DV, Karanjawala Z, Modrak DE, et al. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 2007;13:7380
   PubMed Web of Science ®Google Scholar
• Sultana A, Shore S, Raraty MG, et al. Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer 2009;9:66
   PubMed Web of Science ®Google Scholar
• Chen FM, Taylor CR, Epstein AL. Tumor necrosis treatment of ME-180 human cervical carcinoma model with 131I-labeled TNT-1 monoclonal antibody. Cancer Res 1989;49:4578-85
   PubMed Web of Science ®Google Scholar
• Hornick JL, Sharifi J, Khawli LA, et al. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biother Radiopharm 1998;13:255
   PubMed Web of Science ®Google Scholar
• Dadachova E, Kitchen SG, Bristol G, et al. Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV1 mouse models as a reagent for HIV eradication. PLoS One 2012;7:e31866
   PubMedGoogle Scholar
• Dadachova E, Nakouzi A, Bryan RA, Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA 2003;100:10942
   PubMed Web of Science ®Google Scholar
• Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 2005;77:6288
   PubMed Web of Science ®Google Scholar
• Ocean AJ, Pennington KL, Guarino MJ, et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial. Cancer 2012;118:5497
   PubMed Web of Science ®Google Scholar
• Qu CF, Songl YJ, Rizvi SM, et al. In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213-Bi-CHX.A”-C595. Cancer Biol Ther 2005;4:848
   PubMed Web of Science ®Google Scholar
• Milenic DE, Garmestani K, Brady ED, et al. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radio-immunoconjugate targeting HER2. Cancer Biother Radiopharm 2005;20:557
   PubMed Web of Science ®Google Scholar
• Song EY, Abbas Rizvi SM, Qu CF, et al. Pharmacokinetics and toxicity of 213 Bi-Labeled PAI2 in preclinical targeted alpha therapy for cancer. Cancer Biol Ther 2007;6:898
   PubMed Web of Science ®Google Scholar
• Dadachova E, Nosanchuk JD, Shi L, et al. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc Natl Acad Sci USA 2004;101:14865
   PubMed Web of Science ®Google Scholar
• Wang X-G, Revskaya E, Bryan RA, et al. Treating cancer as an infectious disease - viral antigens as novel targets for treatment and potential prevention of tumors of viral etiology. PLoS One 2007;2:e1114
   Google Scholar
• Dadachova E, Bryan RA, Apostolidis C, et al. Interaction of radiolabeled antibodies with fungal cells and components of immune system in vitro and during radioimmunotherapy of experimental fungal infection. J Infect Dis 2006;193:1427
   PubMed Web of Science ®Google Scholar
• Chen FM, Epstein AL, Li Z, et al. A comparative autoradiographic study demonstrating differential intra-tumor localization of monoclonal antibodies to cell surface (Lym-1) and intracellular (TNT-1) antigens. J Nucl Med 1990;31:1059-66
   PubMed Web of Science ®Google Scholar
• Phaeton R, Harris M, Jiang Z, et al. Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6. Cancer Biol Ther 2010;10:1041
   PubMed Web of Science ®Google Scholar
• Harris M, Wang XG, Jiang Z, et al. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line. Head Neck Oncol 2011;3:9
   Google Scholar
• Jandl T, Revskaya E, Jiang Z, et al. Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma. Immunotherapy 2013;5:357
   Google Scholar
• Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA 1992;89:5645
   PubMed Web of Science ®Google Scholar
• Bouvet M, Wang J, Nardin SR, et al. Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res 2002;62:1534
   PubMed Web of Science ®Google Scholar
• Katz MH, Takimoto S, Spivak D, et al. A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. J Surg Res 2003;113:151
   PubMed Web of Science ®Google Scholar